Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude pour évaluer l'efficacité, l'innocuité, la pharmacocinétique et la pharmacodynamique de l'emicizumab sous-cutané chez des participants de la naissance à 12 mois atteints d'hémophilie A sans inhibiteurs (HAVEN 7)

30 septembre 2026 mis à jour par: Hoffmann-La Roche

Une étude de phase IIIb, multicentrique, ouverte et à un seul bras pour évaluer l'efficacité, l'innocuité, la pharmacocinétique et la pharmacodynamique de l'emicizumab sous-cutané chez des patients de la naissance à 12 mois atteints d'hémophilie A sans inhibiteurs

This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A (intrinsic factor VIII [FVIII] level <1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 milligrams per kilogram of body weight (mg/kg) once every 2 weeks (Q2W) for 52 weeks. After 1 year of treatment, participants will continue to receive emicizumab (1.5 mg/kg once every week [QW], 3 mg/kg Q2W or 6 mg/kg once every 4 weeks [Q4W]) over a 7-year long-term follow-up period under this study frame.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

55

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Johannesburg, Afrique du Sud, 2193
        • Charlotte Maxeke Johannesburg Hospital
      • Bonn, Allemagne, 53127
        • Universitätsklinikum Bonn
      • Mörfelden-Walldorf, Allemagne, 64546
        • Hämophilie-Zentrum Rhein Main GmbH
    • New South Wales
      • Westmead, New South Wales, Australie, 2145
        • The Children's Hospital at Westmead
    • Victoria
      • Parkville, Victoria, Australie, 3052
        • Royal Children's Hospital
    • Western Australia
      • Nedlands, Western Australia, Australie, 6009
        • Perth Children's Hospital
      • Brussels, Belgique, 1200
        • Cliniques Universitaires St-Luc
      • Leuven, Belgique, 3000
        • UZ Leuven Gasthuisberg
    • São Paulo
      • Ribeirão Preto, São Paulo, Brésil, 14051-140
        • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L1
        • Children's Hospital of Eastern Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
      • Madrid, Espagne, 28046
        • Hospital Universitario la Paz
      • Seville, Espagne, 41013
        • Hospital Universitario Virgen del Rocio
    • Barcelona
      • Esplugues de Llobregat, Barcelona, Espagne, 08950
        • Hospital Sant Joan de Deu
      • Paris, France, 75015
        • Groupe Hospitalier Necker Enfants Malades
      • Tel HaShomer, Israël, 5262100
        • Sheba Medical Center - National Hemophilia Center
    • Campania
      • Naples, Campania, Italie, 80123
        • AORN Santobono Pausilipon
    • Emilia-Romagna
      • Parma, Emilia-Romagna, Italie, 43126
        • AOU di Parma
    • Lombardy
      • Milan, Lombardy, Italie, 20122
        • IRCCS Ca' Granda Ospedale Maggiore Policlinico
    • Tuscany
      • Florence, Tuscany, Italie, 50134
        • AOU Careggi
      • Vienna, L'Autriche, 1090
        • Medizinische Universität Wien
      • Glasgow, Royaume-Uni, G51 4TF
        • Queen Elizabeth University Hospital
      • Adana, Turquie (Türkiye), 01130
        • Adana Acibadem Hospital
      • Ankara, Turquie (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Izmir, Turquie (Türkiye), 35100
        • Ege University, School of Medicine
      • Samsun, Turquie (Türkiye), 55139
        • Ondokuz Mayis Univ. Med. Fac.
    • Arizona
      • Phoenix, Arizona, États-Unis, 85016
        • Phoenix Children's Hospital
    • California
      • Los Angeles, California, États-Unis, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • University of Colorado Denver, Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, États-Unis, 70112
        • Tulane University Health Sciences Center
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109-0934
        • University of Michigan
    • Washington
      • Seattle, Washington, États-Unis, 98105
        • Seattle Children's Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

1 seconde à 1 an (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age from birth to ≤12 months at time of informed consent
  • Body weight ≥3 kilograms (kg) at time of informed consent. Patients with a lower body weight can be enrolled after they have reached a body weight of 3 kg. Premature babies (gestational age <38 weeks) may be enrolled as long as they have reached a body weight of 3 kg. For premature babies, the corrected gestational age should be reported.
  • Mandatory receipt of vitamin K prophylaxis according to local standard practice
  • Diagnosis of severe congenital hemophilia A (intrinsic FVIII level <1%)
  • A negative test for FVIII inhibitor (i.e., <0.6 Bethesda units [BU]/mL) locally assessed during the 2-week screening period
  • No history of documented FVIII inhibitor (i.e., <0.6 BU/mL), FVIII drug-elimination half-life <6 hours, or FVIII recovery <66%
  • Previously untreated patients or minimally treated patients (i.e., up to 5 days of exposure with hemophilia-related treatments, such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products)
  • Documentation of the details of the hemophilia-related treatments received since birth
  • Documentation of the details of the bleeding episodes since birth
  • For patients from birth to <3 months of age at the time of study entry: no evidence of active intracranial hemorrhage, as confirmed by a negative cranial ultrasound at screening irrespective of delivery mode
  • Adequate hematologic, hepatic, and renal function, as defined in the protocol
  • For parents/caregivers: willingness and ability to comply with the study protocol requirements, scheduled visits, treatment plans, laboratory tests, completion of applicable questionnaires, and other study procedures

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than severe hemophilia A
  • Use of systemic immunomodulators (e.g., interferon) at enrollment or planned use during the study
  • Receipt of any of the following: Prior use of emicizumab prophylaxis including investigational or commercial emicizumab; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 drug-elimination half-lives of last drug administration; A non-hemophilia-related investigational drug within the last 30 days or 5 drug-elimination half-lives, whichever is shorter; An investigational drug concurrently
  • Current active severe bleed, such as intracranial hemorrhage
  • Planned surgery (excluding minor procedures, e.g., circumcision, CVAD placement) during the study
  • History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
  • Patients who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA, such as thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome) in the investigator's judgment
  • Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis in patients for whom anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
  • Any hereditary or acquired maternal condition that may predispose the patient to thrombotic events (e.g., inherited thrombophilias antiphospholipid syndrome)
  • Other diseases (e.g., certain autoimmune diseases) that may increase risk of bleeding or thrombosis
  • Known infection with HIV, hepatitis B virus, or hepatitis C virus
  • Serious infection requiring antibiotics or antiviral treatments within 14 days prior to screening
  • Concurrent disease, treatment, abnormality in clinical laboratory tests, vital signs measurements, or physical examination findings that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patient's safe participation in and completion of the study or interpretation of the study results
  • Unwillingness of the parent or caregiver to allow receipt of blood or blood products, or any standard-of-care treatment for a life-threatening condition
  • Any other medical, social, or other condition that may prevent adequate compliance with the study protocol in the opinion of the investigator

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Émicizumab

Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.

At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.

During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.

Autres noms:
  • Hemlibra
  • RO5534262
  • RG6013
  • ACE910

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Model-Based Annualized Bleeding Rate for Treated Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for All Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for All Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for All Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Joint Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds
Délai: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Concentrations plasmatiques minimales (Ctrough) d'emicizumab
Délai: Prédose aux semaines 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53
Prédose aux semaines 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53
Incidence des anticorps anti-émicizumab
Délai: Semaines 1, 5, 17, 29, 41 et 53, et par la suite selon les indications cliniques jusqu'à la fin de l'étude (jusqu'à 8 ans)
Semaines 1, 5, 17, 29, 41 et 53, et par la suite selon les indications cliniques jusqu'à la fin de l'étude (jusqu'à 8 ans)
Score total de score de santé articulaire de l'hémophilie (HJHS) à des moments spécifiés au cours de la période de suivi à long terme
Délai: Aux années 4, 5, 6, 7 et 8 du suivi
Aux années 4, 5, 6, 7 et 8 du suivi
Score d'imagerie par résonance magnétique (IRM) d'articulations spécifiques à des moments spécifiés au cours de la période de suivi à long terme
Délai: Aux années 5 et 8 de suivi
Aux années 5 et 8 de suivi
Incidence et gravité des événements indésirables, la gravité étant déterminée selon l'échelle de notation de la toxicité de l'Organisation mondiale de la santé (OMS)
Délai: De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
Incidence des événements thromboemboliques
Délai: De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
Incidence de la microangiopathie thrombotique
Délai: De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
Incidence et gravité des réactions au site d'injection, la gravité étant déterminée selon l'échelle de notation de la toxicité de l'OMS
Délai: De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
Incidence des événements d'hypersensibilité sévère, d'anaphylaxie et d'anaphylactoïde
Délai: De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
Incidence des événements indésirables ayant conduit à l'arrêt du médicament à l'étude
Délai: De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
De la première dose d'emicizumab jusqu'à la fin de l'étude (8 ans)
Changement par rapport à la ligne de base de la fréquence du pouls au fil du temps
Délai: Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Changement par rapport à la ligne de base de la fréquence respiratoire au fil du temps
Délai: Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Changement par rapport à la valeur de référence de la température corporelle au fil du temps
Délai: Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Changement par rapport à la valeur initiale de la pression artérielle systolique au fil du temps
Délai: Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Changement par rapport à la valeur initiale de la pression artérielle diastolique au fil du temps
Délai: Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Base de référence, semaines 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 et 53, et annuellement pendant les 7 ans de suivi. période jusqu'à la fin des études (jusqu'à 8 ans)
Number of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline
Délai: Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53

Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available.

Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53
Incidence of De Novo Development of Factor VIII Inhibitors
Délai: As clinically indicated from baseline until study completion (up to 8 years)

As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered.

As clinically indicated from baseline until study completion (up to 8 years)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Clinical Trials, Hoffmann-La Roche

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

4 février 2021

Achèvement primaire (Réel)

22 mai 2023

Achèvement de l'étude (Estimé)

18 mai 2030

Dates d'inscription aux études

Première soumission

11 juin 2020

Première soumission répondant aux critères de contrôle qualité

11 juin 2020

Première publication (Réel)

16 juin 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • MO41787
  • 2020-001733-12 (Numéro EudraCT)
  • 2023-505964-13-00 (Identificateur de registre: EU CT Number)
  • 2023 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner